Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06325930 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6
A Phase 1 study, sponsored by Rivus Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT06325930 is a Phase 1 study that has completed, run by Rivus Pharmaceuticals. The registered enrollment target is 8 participants.
The verdict
NCT06325930, a Phase 1 study, has completed, sponsored by Rivus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a single-center, non-randomized, open-label Phase 1 study to characterize the absorption, metabolism, excretion, mass balance, pharmacokinetics (PK), safety and tolerability of HU6 following administration of a single dose of \[14C\]-HU6 in a fed state with a standard meal administered approximately 15 minutes prior to dosing.
Interventions
- DRUG [14C]-HU6
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2024-03-26 |
| Est. Completion | 2024-05-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06325930
The ClinicalTrials.gov registry entry for NCT06325930 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rivus Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [14C]-HU6 is the first listed.
NCT06325930 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06325930 about?
NCT06325930 is a clinical study titled "A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6". This is a single-center, non-randomized, open-label Phase 1 study to characterize the absorption, metabolism, excretion, mass balance, pharmacokinetics (PK), safety and tolerability of HU6 following administration of a single dose of \[14C\]-HU6 in a fed state with a standard meal administered appro...
What is the current status of trial NCT06325930?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2024-03-26. Estimated completion is 2024-05-07.
What interventions are being tested in trial NCT06325930?
The interventions under investigation include: [14C]-HU6 (DRUG).
Who is sponsoring clinical trial NCT06325930?
This trial is sponsored by Rivus Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.